BHVNBiohaven Pharmaceutical Holding Company Ltd
$11.41
$0.09
(0.79%)
Closed $11.28
$0.13
(1.15%)
After Hours
EarningsAug 10
Mkt Cap$1.7B
Vol2.36M
Fundamentals
Mkt Cap
$1.7B
Volume
-
52W High
$18.57
52W Low
$7.48
PE Ratio
-1.99
Avg. Volume
2.44M
EPS (Annual)
-$6.86
Rev/Employee
$0.00
Earnings
Aug 10
Why Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?
TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Myriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue?
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation PR Newswire NEW HAVEN, Conn., June 1, 2026...
PR Newswire
Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy
Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE...
PR Newswire
Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control...
PR Newswire
Biohaven (NYSE:BHVN) Trading Down 7.7% After Analyst Downgrade
Biohaven (NYSE:BHVN) Stock Price Down 7.7% on Analyst Downgrade...
MarketBeat
Biohaven Ltd. (BHVN) Upgraded to Buy: Here's Why
Biohaven Ltd. (BHVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
Biohaven (NYSE:BHVN) Price Target Cut to $22.00 by Analysts at Royal Bank Of Canada
Royal Bank Of Canada decreased their price objective on shares of Biohaven from $23.00 to $22.00 and set an "outperform" rating on the stock in a report on Tuesday...
MarketBeat
Biohaven (NYSE:BHVN) Releases Quarterly Earnings Results, Beats Estimates By $0.17 EPS
Biohaven (NYSE:BHVN - Get Free Report) issued its earnings results on Monday. The company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.86) by $0.17...
MarketBeat
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results PR Newswire NEW HAVEN...
PR Newswire
<
1
2
...
>